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As we have stated in our review, significant disagreement exists on the 
definition of additivity (zero interaction), which was reiterated in the preceding 
letter. The definition of expected additivity is crucial because synergy is defined 
as being greater than the expected effect, and antagonism is defined as being 
less than the expected effect. The current three-dimensional (3-D) analytical 
methods (Greco et al., 1990; Prichard and Shipman Jr., 1990; and Sfihnel, 1990) 
all calculate additivity differently. 
The methods proposed by Siihnel and Greco et al. are based on the work of 
Berenbaum (1985, 1989). Berenbaum assumed that linear isobolograms always 
show 'zero interaction' or additivity and proposed 'the general solution' 
(eqn. 1): 
i Xi Yi 
~, + - 1 (1) 
n=l Xi Yi 
In this equation, 'X" is equal to the concentration of drug X that produces an 
effect and 'Y" is equal to the concentration of drug Y that produces the same 
effect; 'x' and 'y' are equal to all combinations of concentrations of the first and 
second drugs, respectively, which in combination produce the same effect as do 
X and Y individually. 
Berenbaum assumed that all additive isobolograms would be linear and 
designed a general equation (eqn. 1) which produces linear isobolograms 
without regard to the shape of the individual dose-response curves. Sfihnel cites 
proofs contained in the 1985 Berenbaum publication and claims that they 
demonstrate that the assumptions used by our method (Prichard and Shipman 
Jr., 1990) are not always valid. These proofs, however, merely show that our 
method typically does not produce linear isobolograms. 
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We do not agree with either the line of thought proposed by Berenbaum or his 
general equation inasmuch as they are based on the premise that additive (zero 
interaction) isobolograms will always be linear. Isobolograms were developed 
initially as tools to describe 3-D surfaces (Loewe, 1953) and are equivalent to 
horizontal cross-sections through the 3-D dose-response surface (reviewed in 
Prichard and Shipman Jr., 1990). When a drug is used in mock-combination 
with itself, the resulting isobolograms are linear. However, the conclusion that 
all additive isobolograms are linear is unfounded. Even Loewe who first 
described isobolograms, doubted that this was the case (see Loewe, 1953). 
Isobolograms are linear in the special case of  a drug versus itself because the 
isobologram is also a line of equal drug concentration. Using eqn. I as an 
example, the isobologram of a drug versus itself is linear not because eqn. 1 is 
generally applicable, but because in the special case of a drug versus itself: 
X Y = x + y .  
In our opinion, the fact that Berenbaum's method yields linear isobolograms 
irrespective of  the shape of  the individual dose-response curves argues that his 
equations are inappropriate. The probability that two unrelated nonlinear 
functions will interact to produce a 3-D surface with linear horizontal cross- 
sections is remote. In general, nonlinear functions and relationships between 
nonlinear functions, as in the case of  dose-response curves, are extremely 
complex and are generally unpredictable and unsolvable (Gleick, 1987; 
Stewart, 1989). Given this fact, a general equation relating drug concentration 
and effect to predict the combined inhibition of two drugs in combination 
probably does not exist. 
Nevertheless, the concept of synergy has merit and can be applied to relevant 
problems. It is a concept which describes the interaction between two or more 
drugs to produce a desired effect. The analysis of this relationship is important 
in choosing optimal drug combinations.  Although it is impossible to 
mathematically predict the interaction of  two drugs, even with detailed 
information about the mechanisms of action, interpretations of  the 3-D dose- 
response surface are meaningful. We have developed a system, partially 
outlined in our review, which describes the nature of the 3-D surface. Because 
the mathematical prediction of  additive interactions is impossible, we assume 
that the two drugs will act according to target theory (dissimilar site 
assumption) and use this surface as an approximation of  additivity. The 
additive dose-response surface (dissimilar site assumption) is calculated with 
the following equation: 
z =  x +  v ( 1 - x )  (2) 
with Z equal to the inhibition produced by the combination, and X and Y equal 
to the inhibition produced by drugs X and Y, respectively. This assumption 
relates the final effects of  the drugs used individually and eliminates the need 
for a general mathematical relationship (which does not exist) between the 
combination of  doses and the final effect. Our method quantitates and analyzes 
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statistically the interactions with respect to this assumption. There are inherent 
limits to target theory, but it is a reasonable approximation of additivity and 
the quantitation of the observed effects makes the comparison of drug 
combinations possible. It also could be argued that the binding of one inhibitor 
could preclude the binding of a second molecule and, consequently, the 
inhibition could be described by the relation: 
Z = X + Y (3) 
again with Z equal to the inhibition produced by the combination, and X and Y 
equal to the inhibition produced by drugs X and Y, respectively, when used 
individually (similar site assumption). We feel that the dissimilar site 
assumption, however, is a generally more appropriate estimation of additive 
effects. 
Our method subtracts the estimated additivity (using either eqn. 1 or 2) from 
the experimental dose-response surface to reveal regions of synergy and 
antagonism. The volume of the synergy peaks is a measure of the quantity of 
synergy observed and is in units of  ~M2%. This is, of course, the 3-D 
counterpart to the area under a dose-response curve (ttM%). Similarly, the 
volume of the inverted (i.e. negative) peaks is a measure of the antagonism. 
We have shown that the equation proposed by Berenbaum (1985) is 
inappropriate inasmuch as it is based on the incorrect premise that all additive 
isobolograms are linear. The methods proposed by Sfihnel and Greco et al. are 
based upon Berenbaum's equation and consequently should be used with 
caution. Additionally, these methods are not quantitative. The quantitation of 
synergy is essential. In order to identify useful chemotherapeutic combinations, 
it is imperative to characterize the relationship and ask: (1) how much synergy 
is produced? (2) at what concentrations and ratios of concentrations does this 
occur? and (3) at what concentrations (if any) are the drugs synergistically 
cytotoxic? Three-dimensional methods are essential to answer these questions. 
Our method is uniquely suited as it is the only one that quantitates statistically 
significant interactions. 
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